Kapusta Matthew C 4

What Happened

• Matthew C. Kapusta, uniQure’s CEO and Director, exercised options and sold common stock in transactions dated June 17–18, 2026. He exercised a total of 67,237 shares (62,581 on 6/17 at $19.39; 4,656 on 6/18 at $31.71) for a reported cost of about $1.36M. He sold 206,100 shares across the two days in multiple open‑market transactions, generating total proceeds of approximately $9.37M. The combined activity appears to be an exercise of vested options followed by immediate or near‑immediate sales (i.e., monetization of option shares).

Key Details

• Transaction dates: June 17–18, 2026.
• Option exercises: 62,581 shares @ $19.39 (6/17; $1,213,446) and 4,656 shares @ $31.71 (6/18; $147,642).
• Open‑market sales (total): 206,100 shares for aggregate proceeds ≈ $9,371,611 (sales executed at prices ranging roughly from $42.50 to $50.03 across multiple tranches).
• Price notes: Several sales prices are reported as weighted averages with price ranges (see filing footnotes F2–F7 for per‑tranche ranges).
• Plan/authorization: Sales were conducted under a prearranged Rule 10b5‑1 trading plan adopted October 5, 2025 (footnote F1).
• Vesting: Related stock options had vested earlier (footnotes F8 and F9 indicate full vesting in 2022 and 2023).
• Shares owned after transactions: Not specified in the provided summary — see the Form 4 for the filing’s “amount beneficially owned after” line.
• Filing timing: The Form 4 was filed June 22, 2026 for transactions on June 17–18. That interval is longer than the typical two business‑day Form 4 filing window, so the filing may be late; check the submitted Form 4 for any late‑filing designation.

Context

• These entries are reported as option exercises (transaction code M) followed by sales (S). When an insider exercises options and then sells the acquired shares the same day or shortly after, it typically reflects a cashless or monetization transaction (exercise + sell), rather than a fresh purchase that signals new bullishness.
• The presence of a 10b5‑1 plan indicates the sales were prearranged and not necessarily based on contemporaneous, undisclosed company information. As always, filings are factual records of transactions and do not state the insider’s motivations.